This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kostenuik, P. J. Articles by Dunstan, C. R. Search for Related Content PubMed PubMed Citation Articles by Kostenuik, P. J. Articles by Dunstan, C. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats

Departments of Pharmacology/Pathology (P.J.K., C.C., S.M., S.A., D.L.L.), Process Development (G.S.), and Development (C.R.D.), Amgen, Inc., Thousand Oaks, California 91320; and Skeletech (V.S.), Bothell, Washington 98021

Address all correspondence and requests for reprints to: Dr. Paul J. Kostenuik, Department of Pathology/Pharmacology, One Amgen Center Drive, Thousand Oaks, California 91320. E-mail: paulk{at}amgen.com

PTH is a potent bone anabolic factor, and its combination with antiresorptive agents has been proposed as a therapy for osteoporosis. We tested the effects of PTH, alone and in combination with the novel antiresorptive agent OPG, in a rat model of severe osteopenia. Sprague Dawley rats were sham-operated or ovariectomized at 3 months of age. Rats were untreated for 15 months, at which time ovariectomy had caused significant decreases in bone mineral density in the lumbar vertebrae and femur. Rats were then treated for 5.5 months with vehicle (PBS), human PTH-(1–34) (80 µg/kg), rat OPG (10 mg/kg), or OPG plus PTH (all three times per wk, sc). Treatment of ovariectomized rats with OPG or PTH alone increased bone mineral density in the lumbar vertebrae and femur, whereas PTH plus OPG caused significantly greater and more rapid increases than either therapy alone (P < 0.05). OPG significantly reduced osteoclast surface in the lumbar vertebrae and femur (P < 0.05 vs. sham or ovariectomized), but had no effect on osteoblast surface at either site. Ovariectomy significantly decreased the mechanical strength of the lumbar vertebrae and femur. In the lumbar vertebrae, OPG plus PTH was significantly more effective than PTH alone at reversing ovariectomy-induced deficits in stiffness and elastic modulus. These data suggest that OPG plus PTH represent a potentially useful therapeutic option for patients with severe osteoporosis.

This article has been cited by other articles:

				E. J. Samelson, K. E. Broe, S. Demissie, T. J. Beck, D. Karasik, S. Kathiresan, and D. P. Kiel Increased Plasma Osteoprotegerin Concentrations Are Associated with Indices of Bone Strength of the Hip J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1789 - 1795. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				S. Ferrari Are Osteoclasts Necessary for PTH Anabolism? A Reappraisal from Osteoprotegerin Studies IBMS BoneKEy, October 1, 2007; 4(10): 278 - 281. [Full Text] [PDF]

				R. Samadfam, Q. Xia, and D. Goltzman Pretreatment with Anticatabolic Agents Blunts But Does Not Eliminate the Skeletal Anabolic Response to Parathyroid Hormone in Oophorectomized Mice Endocrinology, June 1, 2007; 148(6): 2778 - 2787. [Abstract] [Full Text] [PDF]

				A. J. Koh, B. Demiralp, K. G. Neiva, J. Hooten, R. M. Nohutcu, H. Shim, N. S. Datta, R. S. Taichman, and L. K. McCauley Cells of the Osteoclast Lineage as Mediators of the Anabolic Actions of Parathyroid Hormone in Bone Endocrinology, November 1, 2005; 146(11): 4584 - 4596. [Abstract] [Full Text] [PDF]

				S. Morony, K. Warmington, S. Adamu, F. Asuncion, Z. Geng, M. Grisanti, H. L. Tan, C. Capparelli, C. Starnes, B. Weimann, et al. The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy Endocrinology, August 1, 2005; 146(8): 3235 - 3243. [Abstract] [Full Text] [PDF]

				F R Byrne, S Morony, K Warmington, Z Geng, H L Brown, S A Flores, M Fiorino, S L Yin, D Hill, V Porkess, et al. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin Gut, January 1, 2005; 54(1): 78 - 86. [Abstract] [Full Text] [PDF]

				K. Redlich, B. Gortz, S. Hayer, J. Zwerina, N. Doerr, P. Kostenuik, H. Bergmeister, G. Kollias, G. Steiner, J. S. Smolen, et al. Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis Am. J. Pathol., February 1, 2004; 164(2): 543 - 555. [Abstract] [Full Text] [PDF]

				B. Bolon, S. Morony, Y. Cheng, Y.-L. Hu, and U. Feige Osteoclast Numbers in Lewis Rats with Adjuvant-induced Arthritis: Identification of Preferred Sites and Parameters for Rapid Quantitative Analysis Vet. Pathol., January 1, 2004; 41(1): 30 - 36. [Abstract] [Full Text] [PDF]